Precision BioSciences (DTIL) Financials: History & Chart

Precision BioSciences, Inc.(DTIL)

Biotechnology · Durham, NC

$6.33+0.02 (+0.24%)

Delayed quote: Oct 6, 2026, 11:35 AM EDT

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.

Durham, NC

67 employees

www.precisionbiosciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael Amoroso

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	45.05M	0.00	10.84M	34.20M	13K	18K	29K	638K	576K
Cost of Goods Sold	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	45.05M	0.00	10.84M	34.20M	13K	18K	29K	638K	576K
Gross Profit Margin	100.0%	N/A	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	81.45M	19.16M	19.91M	21.70M	20.68M	21.89M	22.14M	25.48M	21.85M
Research & Development	53.32M	12.39M	13.11M	14.46M	13.35M	12.77M	13.59M	15.91M	13.08M
Selling, General & Administrative	28.13M	6.77M	6.80M	7.23M	7.33M	9.13M	8.55M	9.58M	8.77M
Operating Income (EBIT)	-36.40M	-19.16M	-9.07M	12.51M	-20.67M	-21.88M	-22.11M	-24.85M	-21.27M
Operating Margin	-80.8%	N/A	-83.7%	36.6%	-158976.9%	-121538.9%	-76248.3%	-3894.4%	-3693.6%
Income Before Tax (EBT)	-53.62M	-32.65M	-18.44M	19.25M	-21.77M	-23.52M	-20.57M	-17.75M	-16.43M
Interest Income	3.74M	943K	999K	773K	1.03M	1.12M	1.32M	1.49M	1.76M
Interest Expense	1.32M	300K	311K	348K	362K	358K	354K	392K	256K
Other Income/Expense	-17.22M	-13.49M	-9.37M	6.74M	-1.10M	-1.64M	1.55M	7.10M	4.85M
Net Income	-52.73M	-32.65M	-18.44M	20.13M	-21.77M	-23.52M	-20.57M	-17.75M	-16.43M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-117.0%	N/A	-170.2%	58.9%	-167476.9%	-130666.7%	-70913.8%	-2781.3%	-2851.6%
EBITDA	-34.15M	-18.91M	-8.44M	13.19M	-19.99M	-21.18M	-21.41M	-24.09M	-20.26M
EBITDA Margin	-75.8%	N/A	-77.8%	38.6%	-153792.3%	-117672.2%	-73817.2%	-3775.7%	-3518.1%
Depreciation & Amortization	2.25M	253K	640K	678K	674K	696K	705K	757K	1.01M
EPS Basic	-2.79	-1.26	-0.75	1.06	-1.84	-2.13	-2.30	-2.51	-2.25
EPS Diluted	-2.80	-1.26	-0.75	1.05	-1.84	-2.13	-2.29	-2.50	-2.25
Weighted Average Basic Shares	25.86M	25.86M	24.63M	19.05M	11.82M	11.05M	8.94M	6.83M	7.29M
Weighted Average Diluted Shares	25.86M	25.86M	24.63M	19.17M	11.82M	11.05M	8.97M	6.88M	7.29M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	34.26M	68.70M	48.73M	25.10M	115.53M	24.29M	22.24M	10.88M
Cost of Goods Sold	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	34.26M	68.70M	48.73M	25.10M	115.53M	24.29M	22.24M	10.88M
Gross Profit Margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	86.41M	94.86M	92.46M	87.41M	154.91M	134.11M	109.44M	58.80M
Research & Development	54.17M	59.56M	53.38M	46.12M	115.24M	98.06M	82.42M	45.12M
Selling, General & Administrative	32.24M	35.30M	39.09M	41.28M	39.67M	36.05M	27.03M	13.67M
Operating Income (EBIT)	-52.15M	-26.16M	-43.74M	-62.31M	-39.38M	-109.83M	-87.20M	-47.91M
Operating Margin	-152.2%	-38.1%	-89.8%	-248.3%	-34.1%	-452.2%	-392.1%	-440.2%
Income Before Tax (EBT)	-46.61M	7.17M	-42.53M	-72.91M	-30.60M	-109.01M	-92.88M	-46.04M
Interest Income	4.24M	6.76M	7.69M	3.47M	208K	822K	4.27M	1.88M
Interest Expense	1.42M	1.78M	2.23M	1.11M	132K	N/A	182K	N/A
Other Income/Expense	5.54M	33.33M	1.21M	-10.60M	8.77M	822K	-5.67M	1.88M
Net Income	-45.72M	7.17M	-61.32M	-111.64M	-30.60M	-109.01M	-92.88M	-46.04M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-133.4%	10.4%	-125.8%	-444.8%	-26.5%	-448.9%	-417.6%	-423.0%
EBITDA	-49.40M	-21.59M	-35.48M	-53.30M	-29.18M	-100.02M	-81.89M	-45.56M
EBITDA Margin	-144.2%	-31.4%	-72.8%	-212.4%	-25.3%	-411.8%	-368.2%	-418.6%
Depreciation & Amortization	2.75M	4.58M	8.26M	9.00M	10.20M	9.81M	5.32M	2.35M
EPS Basic	-3.56	1.05	-15.96	-38.10	-15.60	-62.85	-59.50	-28.17
EPS Diluted	-3.56	1.04	-15.96	-38.10	-15.60	-62.85	-59.50	-28.17
Weighted Average Basic Shares	12.83M	6.83M	3.84M	2.93M	1.96M	1.73M	1.40M	1.63M
Weighted Average Diluted Shares	12.83M	6.88M	3.84M	2.93M	1.96M	1.73M	1.40M	1.63M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.